Cytosorbents (CTSO) CFO Peter Mariani Buys $44K of Stock
Cytosorbents CFO Peter Mariani acquired 100,000 shares worth $44,000 on June 15.
Reviewed by automated data checks against the source filing. How we make and check alerts
Peter Mariani, Chief Financial Officer at Cytosorbents Corporation ($CTSO), bought 100,000 shares at an average price of $0.44, worth about $44,000, on June 15, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CTSO is down 4.4% after 1 week, down 9.9% after 1 month and down 52.4% to date (from the $8.64 close on Jun 15, 2026).
CTSO
Cytosorbents Corporation
Key Points
- On June 15, 2026, CFO Peter Mariani bought 100,000 shares of Cytosorbents at $0.44 each, totaling $44,000.
- Shares of Cytosorbents (NasdaqCM: CTSO) traded around $0.43, with a market cap of $27.1 million.
- Analysts have set a mean target price of $2.88 for Cytosorbents, with a high of $5.00.
Get $CTSO trade alerts by text
We text you when insiders, Congress or big funds trade $CTSO. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Cytosorbents Corporation alert may contain errors. Disclosures
Cytosorbents Corporation's Chief Financial Officer, Peter Mariani, made a significant purchase of the company's stock on June 15, 2026. Mariani acquired 100,000 shares at an average price of $0.44, resulting in a total transaction value of $44,000. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at Cytosorbents Corporation
On the same day, CEO Dr. Phillip Chan also purchased shares, acquiring 10,333 shares at $0.43 each. Earlier, on June 12, Chan bought another 251,136 shares at $0.40. These insider transactions suggest confidence in the company's prospects.
Cytosorbents Corporation Stock Down 92.5%
Shares of Cytosorbents, trading on the NasdaqCM under the ticker CTSO, recently hovered around $0.43. The company has a market capitalization of approximately $27.1 million. Its stock has seen a 52-week low of $0.37 and a high of $1.39. The 50-day moving average stands at $0.55, while the 200-day moving average is $0.71. The company's financial ratios include a current ratio of 1.089, a quick ratio of 0.734, and a high debt-to-equity ratio of 1334.366.
Analysts Set New Price Targets
Analysts have been maintaining their positions on Cytosorbents. On January 12, 2026, D. Boral Capital maintained a 'buy' rating with a price target of $10.00. The general analyst consensus sets a mean target price of $2.88, based on two opinions.
About Cytosorbents Corporation
Cytosorbents Corporation, headquartered in Princeton, New Jersey, is a healthcare company specializing in medical devices. It focuses on blood purification technologies, with its flagship product, CytoSorb, used to treat cytokine storms in critical illnesses. The company operates in the United States, Germany, and internationally, and is led by CEO Dr. Phillip P. Chan.
Bottom Line
The recent insider purchases by CFO Peter Mariani and CEO Dr. Phillip Chan highlight their confidence in Cytosorbents' future. Investors often watch such transactions for insights into company sentiment. While the stock's recent performance has been mixed, analysts maintain a positive outlook with a high target price. However, it's important to remember that insider transactions are just one of many factors investors consider.
Related Filing Alerts
Source: Peter Mariani's Form 4 filing on $CTSO (Jun 15, 2026). Find the original filing: CTSO Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts